Observational Study of NovoNorm® in Subjects With Diabetes

Novo Nordisk

Status: Completed

Conditions: Diabetes; Diabetes Mellitus, Type 2

Treatments: Drug: repaglinide

Study type: Observational

Funder types: Industry

Identifiers

NCT01498913

AGEE-1882

Details and patient eligibility

About

This study is conducted in Asia. The aim of this study is to review the safety and efficacy of Novonorm® (repaglinide) in post-marketing use.

Enrollment: 5,841 patients

Sex: All

Volunteers: No Healthy Volunteers

Inclusion and exclusion criteria

Inclusion Criteria:

• Type 2 diabetes

Trial design

5,841 participants in 1 patient group

Repaglinide

Treatment:

Drug: repaglinide